TOFFOLETTI, Eleonora
 Distribuzione geografica
Continente #
NA - Nord America 2.353
EU - Europa 664
AS - Asia 171
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 2
AF - Africa 1
SA - Sud America 1
Totale 3.195
Nazione #
US - Stati Uniti d'America 2.343
UA - Ucraina 194
IT - Italia 111
CN - Cina 110
DE - Germania 85
SE - Svezia 71
FI - Finlandia 59
IE - Irlanda 35
TR - Turchia 35
BE - Belgio 34
FR - Francia 22
GB - Regno Unito 20
VN - Vietnam 14
CA - Canada 8
IN - India 7
CZ - Repubblica Ceca 6
RO - Romania 4
RU - Federazione Russa 4
AT - Austria 3
BG - Bulgaria 3
CH - Svizzera 3
EU - Europa 3
AU - Australia 2
ES - Italia 2
JP - Giappone 2
KR - Corea 2
PL - Polonia 2
RS - Serbia 2
BR - Brasile 1
EG - Egitto 1
GL - Groenlandia 1
HR - Croazia 1
HU - Ungheria 1
LI - Liechtenstein 1
MX - Messico 1
NL - Olanda 1
SG - Singapore 1
Totale 3.195
Città #
Woodbridge 298
Ann Arbor 284
Chandler 251
Fairfield 238
Houston 172
Ashburn 138
Jacksonville 130
Seattle 108
Wilmington 89
Dearborn 86
Beijing 75
Cambridge 66
Udine 53
Princeton 36
Dublin 35
Izmir 35
Brussels 34
Trieste 22
San Diego 17
Dong Ket 14
Des Moines 11
Ogden 10
New York 8
Redmond 8
Boardman 7
Kunming 6
Grafing 5
Hefei 5
Milan 5
Norwalk 5
Ottawa 5
Phoenix 5
Helsinki 4
Nanjing 4
Philadelphia 4
Prague 4
Atlanta 3
Frankfurt am Main 3
Ningbo 3
Sofia 3
Toronto 3
Vienna 3
Washington 3
Zurich 3
Belgrade 2
Brno 2
Chengdu 2
Guangzhou 2
Hebei 2
Horia 2
Licata 2
Madrid 2
Pune 2
Simi Valley 2
Tokyo 2
Valdobbiadene 2
Warsaw 2
Wuhan 2
Adelaide 1
Amsterdam 1
Baotou 1
Birmingham 1
Bucharest 1
Budapest 1
Catanzaro 1
Cavarzere 1
Chicago 1
Codroipo 1
Drap 1
Edinburgh 1
Fuzhou 1
Hanover 1
Jinan 1
Jinhua 1
Lanzhou 1
Leawood 1
London 1
Marseille 1
Mountain View 1
Nuuk 1
Padova 1
Perth 1
Raleigh 1
Reston 1
Saint Petersburg 1
Schaan 1
Scuola 1
Secaucus 1
Sestri Levante 1
São Paulo 1
Tappahannock 1
Toluca 1
Venezia 1
Wenzhou 1
Zagreb 1
Zhengzhou 1
Totale 2.367
Nome #
BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients 172
Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. 145
Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia 134
Decreased function of Fas and variations of the perforin gene in adult patients with primary immune thrombocytopenia 133
Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors 127
Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years 126
Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. 124
Single step multiple genotyping by MALDI-TOF mass spectrometry, for evaluation of minor histocompatibility antigens in patients submitted to allogeneic stem cell transplantation from HLA-matched related and unrelated donor 124
Clonality and phenotype in spleens from patients with primary immune thrombocytopenia. 117
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 117
Prognostic factors and outcome of Epstein-Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. 113
B-cell immune reconstitution after allogenic stem cell transplantation and its role in the development of chronic graft-versus-host disease 112
Longitudinal follow-up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogeneic bone marrow transplant 109
Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories 106
Expression and modulation of S100A4 protein by human mast cells 106
Targeting kinase-activating genetic lesions to improve therapy of pediatric acute lymphoblastic leukemia 104
Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy. 101
The hidden genomic landscape of acute myeloid leukemia: subclonal structure revealed by undetected mutations. 101
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 97
Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia 96
CONCOMITANT BCRP OVER-EXPRESSION AND FLT3-ITD MUTATION IDENTIFY A SUBSET OF ACUTE MYELOID LEUKEMIA PATIENTS AT HIGH RISK OF RELAPSE 87
KIR POLYMORPHISM IN REDUCED INTENSITY HLA-ID SIBLING STEM CELL TRANSPLANTATION: IMPACT ON CLINICAL OUTCOME 86
T-cell chimerism and clinical outcome after reduced-intensity conditioning allogeneic stem cell transplantation 83
KERATOCONJUNCTIVITIS TREATMENT WITH AUTOLOGOUS SERUM EYE IN PATIENTS WITH SEVERE CHRONIC GVHD 79
No evidence for B-cell clonality by spectratyping analysis in patients with idiopathic thrombocytopenic purpura undergoing rituximab therapy” 74
OUTCOMES AFTER ALLOGENEIC STEM CELL TRANSPLANT FOR REFRACTORY AND RELAPSED ACUTE MYELOID LEUKEMIA 60
Longitudinal follow up of WT1 gene expression as monitoring of minimal residual disease in acute myeloid leukemia following allogenic bone marrow transplant 58
Fludarabine-based induction therapy does not overcome the negative effect of bcrp (ABCG2) overexpression on remission duration in adult de novo acute myeloid leukemia patients 57
MONITORING OF MINIMAL RESIDUAL DISEASE BY QUANTITATIVE WT1 GENE EXPRESSION AFTER REDUCED INTENSITY CONDITIONING ALLOGENEIC SCT IN ACUTE MYELOID LEUKEMIA 56
QUANTITATIVE ANALYSIS OF MN1 GENE EXPRESSION FOR EVALUATION OF MINIMAL RESIDUAL DISEASE IN CYTOGENETICALLY NORMAL ACUTE MYELOID LEUKEMIA PATIENTS 54
CONCOMITANT OVEREXPRESSION OF BCRP AND FLT3-ITD MUTATION ARE ASSOCIATED WITH POOR PROGNOSIS IN ACUTE MYELOID LEUKEMIA PATIENTS 50
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduce intensity conditioning allogenic stem cell transplantation in acute myeloid leukaemia 48
Clinical presentation, outcome and risk factors of late-onset non-infectious pulmonary complication after allogeneic transplantation 48
MULTICENTER PROSPECTIVE CLINICAL TRIAL WITH LOW DOSE GEMTUZUMAB-OZOGAMICIN PLUS FLUDARABINE, CYTARABINE, IDARUBICIN (GO-FLAI) AS INDUCTION THERAPY OF CD33-POSITIVE ACUTE MYELOID LEUKEMIA (AML) PATIENTS YOUNGER THAN 65 YEARS 37
WT1 – Gene expression driven pre-emptive treatment with decitabine for molecular relapse of acute myeloid leukemia after allogeneic stem cell transplant 28
JAK2 V617F-mutated polycythemia vera developing in a patient with a 20-year-long chronic myeloid leukemia at the time of first molecular response 21
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment-free remission: A study from the “GRUPPO TRIVENETO LMC” 11
A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias 11
Optimal timing of molecular monitoring after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia 6
Totale 3.318
Categoria #
all - tutte 8.748
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 8.748


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019230 0 0 0 0 0 0 0 0 2 44 115 69
2019/2020806 50 39 27 129 58 131 84 88 55 73 19 53
2020/2021479 10 44 11 51 15 49 27 47 85 21 87 32
2021/2022368 18 35 16 21 22 9 22 10 10 54 96 55
2022/2023546 52 48 5 80 48 116 7 63 71 14 26 16
2023/2024120 20 18 5 7 28 18 2 8 14 0 0 0
Totale 3.318